First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence
Copyright © 2022 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved..
OBJECTIVE: This study aimed to identify factors predicting pneumonia in adults with coronavirus disease 2019 (COVID-19) during the Omicron variant (B.1.1.529) emergence. We also evaluated, in fully vaccinated (BNT162b2 or AZD1222) individuals, if the time (<6 or ≥6 months) elapsed since the last shot was received was associated with the risk of severe illness.
STUDY DESIGN: A retrospective cohort study was conducted in Mexico.
METHODS: Data from 409,493 were analyzed, and risk ratios (RRs) and 95% confidence intervals (CIs) were computed through generalized linear models.
RESULTS: We documented a total of 3513 COVID-19 pneumonia cases (69.5 per 100,000 person-days). In multiple analyses, a protective effect was observed in vaccinated adults (RR = 0.996, 95% CI 0.995-0.997). Male gender, increasing age, and smoking were associated with a greater risk of pneumonia. Individuals with chronic comorbidities (pulmonary obstructive disease, type 2 diabetes mellitus, arterial hypertension, kidney disease, and immunosuppression) were also at higher risk. Among fully vaccinated subjects (n = 166,869), those who had received the last shot at 6 more months were at increased risk for developing pneumonia (RR = 1.002, 95% CI 1.001-1.003).
CONCLUSIONS: Our results suggest that the first-generation BNT162b2 and AZD1222 vaccines reduce the risk of COVID-19 pneumonia during the Omicron emergence. We also found that adults with longer interval from the administration of the second shot to illness onset were at increased risk of severe manifestations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:207 |
|---|---|
| Enthalten in: |
Public health - 207(2022) vom: 01. Juni, Seite 105-107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murillo-Zamora, E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B5S3K2V0G8 |
|---|
| Anmerkungen: |
Date Completed 21.06.2022 Date Revised 21.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.puhe.2022.04.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341173991 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341173991 | ||
| 003 | DE-627 | ||
| 005 | 20231226011154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.puhe.2022.04.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341173991 | ||
| 035 | |a (NLM)35594806 | ||
| 035 | |a (PII)S0033-3506(22)00105-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murillo-Zamora, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2022 | ||
| 500 | |a Date Revised 21.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVE: This study aimed to identify factors predicting pneumonia in adults with coronavirus disease 2019 (COVID-19) during the Omicron variant (B.1.1.529) emergence. We also evaluated, in fully vaccinated (BNT162b2 or AZD1222) individuals, if the time (<6 or ≥6 months) elapsed since the last shot was received was associated with the risk of severe illness | ||
| 520 | |a STUDY DESIGN: A retrospective cohort study was conducted in Mexico | ||
| 520 | |a METHODS: Data from 409,493 were analyzed, and risk ratios (RRs) and 95% confidence intervals (CIs) were computed through generalized linear models | ||
| 520 | |a RESULTS: We documented a total of 3513 COVID-19 pneumonia cases (69.5 per 100,000 person-days). In multiple analyses, a protective effect was observed in vaccinated adults (RR = 0.996, 95% CI 0.995-0.997). Male gender, increasing age, and smoking were associated with a greater risk of pneumonia. Individuals with chronic comorbidities (pulmonary obstructive disease, type 2 diabetes mellitus, arterial hypertension, kidney disease, and immunosuppression) were also at higher risk. Among fully vaccinated subjects (n = 166,869), those who had received the last shot at 6 more months were at increased risk for developing pneumonia (RR = 1.002, 95% CI 1.001-1.003) | ||
| 520 | |a CONCLUSIONS: Our results suggest that the first-generation BNT162b2 and AZD1222 vaccines reduce the risk of COVID-19 pneumonia during the Omicron emergence. We also found that adults with longer interval from the administration of the second shot to illness onset were at increased risk of severe manifestations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BNT162 vaccine | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ChAdOx1 nCoV-19 | |
| 650 | 4 | |a Pneumonia | |
| 650 | 4 | |a SARS-CoV-2 variants | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Trujillo, X |e verfasserin |4 aut | |
| 700 | 1 | |a Huerta, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ríos-Silva, M |e verfasserin |4 aut | |
| 700 | 1 | |a Lugo-Radillo, A |e verfasserin |4 aut | |
| 700 | 1 | |a Baltazar-Rodríguez, L M |e verfasserin |4 aut | |
| 700 | 1 | |a Mendoza-Cano, O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Public health |d 1945 |g 207(2022) vom: 01. Juni, Seite 105-107 |w (DE-627)NLM000433977 |x 1476-5616 |7 nnns |
| 773 | 1 | 8 | |g volume:207 |g year:2022 |g day:01 |g month:06 |g pages:105-107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.puhe.2022.04.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 207 |j 2022 |b 01 |c 06 |h 105-107 | ||